McGovern Medical School, Sino Biological Inc., and the Gulf Coast Consortia, will host the Fourth Annual Symposium of the CPRIT Therapeutic Antibody Core, Dec. 10 at the Sarofim Research Building (1825 Pressler St.).
The symposium will be held from 11:30 a.m.-5:30 p.m., and showcases the core’s state-of-the-art technology platforms and multiple successful research programs. Attendees will learn about exciting opportunities to advance translational research, particularly for the development of cancer antibody drugs.
Talks will be held in the Beth Robertson Auditorium of the Brown Foundation Institute of Molecular Medicine (IMM) while the reception will take place in the James T. Willerson, MD, Discovery Hall. Speakers include Zhiqiang An, PhD, director of the CPRIT Therapeutic Antibody Core; and Barry Morgan, PhD, visiting professor at McGovern Medical School; as well as Rob Burgess, PhD, chief business officer of SinoBiological; Yang-Xin Fu, MD, PhD, professor of pathology at UT Southwestern; Philipp E. Scherer, PhD, professor of internal medicine at UT Southwestern; William R. Strohl, PhD, president of BiStro Biotech Consulting LLC; and Guo-Liang Yu, PhD, chairman & CEO of Apollomics.
The core makes specialized antibody engineering technologies, services, and expertise available to Texas-based researchers. This support tackles major obstacles to advancing discoveries beyond the discovery stage toward the development of new treatments.
Key members of the core include a Scientific Advisory Board (SAB) and PI’s of associated projects.
Now in its fifth year of operation, the CPRIT Therapeutic Antibody core has enabled access to multiple antibody sources for drug lead identification, including phage displayed human antibody libraries. The core has additionally installed and begun operations with several specialized instruments.
Annually the core conducts an SAB meeting and a symposium. The CPRIT Therapeutic Antibody Core is a member of the UT System iLabs Solutions Core Facility Management Software System, which streamlines financial management of the core.
The long-term goal of the core is to continue providing statewide support and service to advance lead antibodies from academic laboratories to the stage of preclinical development. Toward this end, the core is currently seeking to establish new collaborations with researchers seeking to develop cancer therapeutic antibodies.
Any researcher interested in collaborating with the core may submit an application. Following initial consultation and prior to initiation, all projects will be reviewed for feasibility, appropriateness for the available core resources, cancer relevance and scientific merit. Approved requests for projects will be prioritized and scheduled accordingly.